Get started
BIONTECH SE DRNBIONTECH SE DRNBIONTECH SE DRN

BIONTECH SE DRN

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals

B1NT34 chart


Full chart

Key stats


Market capitalization
‪165.40 B‬ BRL
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−11.473 BRL
Net income (FY)
‪4.89 B‬ BRL
Revenue (FY)
‪20.07 B‬ BRL
Shares float
‪239.44 M‬
Beta (1Y)
−0.07

About BioNTech SE


Sector
Health Technology
Industry
Biotechnology
CEO
Ugur Sahin
Website
biontech.de
Headquarters
Mainz
Founded
2008
ISIN
BRB1NTBDR005
FIGI
BBG00XX9JN55
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

B1NT34 news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where B1NT34 is featured.

See all sparks